XTalks
FEBRUARY 8, 2024
The top 15 diabetes drugs in 2023, according to 2022 sales data, reflect the current state of diabetes management and hint at the evolving needs and trends within this critical area of healthcare. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. mL subcutaneous solution (2 mg/1.5
XTalks
NOVEMBER 3, 2022
Mounjaro has thus taken off stronger than expected, surpassing Wall Street sales forecasts during the third quarter. Mounjaro was approved this summer as a Type 2 diabetes treatment and is the first diabetes drug with dual action, targeting two hormones involved in insulin production and appetite (GIP and GLP-1).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT News
DECEMBER 5, 2022
Horizon shares surged over the past week after the company said it is in separate preliminary talks with J&J, Amgen, and Sanofi about a possible sale. Mifepristone, a drug that blocks hormones necessary for pregnancy, was approved by the FDA in 2000. Amgen and Sanofi have said that any offer for Horizon would be cash only.
pharmaphorum
JANUARY 10, 2023
New drugs for immunological and inflammatory diseases feature prominently among new product launches this year that could top $1 billion in annual sales by 2027 or be clinical “game changers,” according to Clarivate.
Delveinsight
DECEMBER 29, 2020
Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist. billion – a deal that is split into upfront payments, and sales and regulatory milestone payments. It is a complication associated with diabetic patients who take insulin and certain anti-diabetic tablets. mg) in the US and Canada.
XTalks
NOVEMBER 9, 2022
Since Mounjaro’s May US Food and Drug Administration (FDA) approval, sales of the drug have skyrocketed beyond initial expectations owing to patient demand and a temporary shortage of Novo’s Ozempic. dependent insulin secretion and suppression of glucagon release. And the demand won’t be easing anytime soon. billion in 2021 to $61.6
Delveinsight
DECEMBER 7, 2020
Unlike most other industries, in MedTech, AI is not confined to sales and operations ends of the value chain. The device is worn on the patients’ body, which contains a biharmonic cartridge in it that carries insulin and glucagon. The device can be configured to inject a specific dose of the hormones into the patient.
Expert insights. Personalized for you.
52 
Let's personalize your content